Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

NCT03144778 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions

BIOLOGICAL: Durvalumab
BIOLOGICAL: Tremelimumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]